Title
Category
Credits
Event date
Cost
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs. David Ilson and Michael Press for this on-demand online activity, as they discuss assessment of HER2-mutant disease from each of their unique perspectives.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo. 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Antibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. Nearly 150 investigational ADCs are currently in pre-clinical and clinical trials. Join Drs. David Ilson and Kohei Shitara as they discuss emerging data from select clinical trials evaluating combinations of HER2-targeted therapies for patients with gastric cancer.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo. 
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Clinicians must be aware and up-to-date on the most effective approaches to management in order to provide patients with the most appropriate course of therapy. Join Drs. David Ilson and Yelena Janjigian as they discuss the rapidly evolving landscape of gastric cancer treatment, focusing on available front- and subsequent-lines of treatment, and how to tailor treatment to patients based on health status, prior lines of therapy, cost, convenience and access to care, genetic aberrations, and availability of a clinical trial.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Heart failure is a major public-health problem resulting in substantial morbidity and mortality for the US. Unfortunately, challenges and barriers to effective use of guideline-directed medical therapies (GDMT) among hospitalized patients with HFrEF remain. Join Drs. Muthiah Vaduganathan and Amulya Nagarur as they discuss practical strategies and insights into using GDMT, and opportunities for multidisciplinary partnerships when treating these patients.Supported through an independent educational grant from Merck.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Join Drs. Muthiah Vaduganathan and Javed Butler for this on-demand online activity, as they examine novel methodologies to address the clinical worsening of HFrEF, with a focus on recently-reported results from the VICTORIA trial.Supported through an independent educational grant from Merck.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Initiating and optimizing in-hospital guideline-directed medical therapies (GDMT) remains a challenge for clinicians treating patients with worsening HFrEF. Join Drs. Muthiah Vaduganathan and Michelle Kittleson, as they discuss opportunities and strategies to employ evidence-based therapies to address these challenges.Supported through an independent educational grant from Merck.